Analysis of serum cytokine levels in patients with pemphigus vulgaris

被引:2
作者
Ucmak, Derya [1 ]
Akkurt, Zeynep Meltem [1 ]
Yuksel, Hatice [2 ]
Arica, Mustafa [1 ]
机构
[1] Dicle Univ, Tip Fak, Dermatol, Diyarbakir, Turkey
[2] Dicle Univ, Tip Fak, Biyokimya Anabilim Dali, Diyarbakir, Turkey
来源
TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY | 2015年 / 49卷 / 01期
关键词
Pemphigus vulgaris; Autoimmune skin disease; Th1; cytokines; Th2;
D O I
10.4274/turkderm.71135
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background and Design: Pemphigus vulgaris (PV) is an autoimmune blistering skin disease. The aim of this study was to compare the levels of T helper 1 (Th1), T helper 2 (Th2) and T helper 17 (Th17) type cytokines in PV patients and healthy controls. Materials and Methods: The study population included 37 patients with PV and 35 healthy individuals. The patients were grouped into mild, moderate and severe disease groups according to the severity of skin and mucosal involvement. Serum interleukin (IL)-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-17A and interferon (IFN)-gamma levels were assessed using the enzyme-linked immunosorbent assay method. Serum cytokine levels were compared between patients and controls and between patient subgroups. Analysis of data was done using SPSS 15.0. Results: Serum IL-2, IL-4, IL-6 levels were significantly higher in the patient group compared to the control group (p<0.001, p<0.001, p<0.001, respectively). IL-6 levels were found to be correlated with the severity of disease (r=0.490, p=0.003). There was no statistically significant difference in serum cytokine levels between the patient subgroups. Conclusion: Th2 type cytokines were found to be increased in serum of patients with pemphigus vulgaris. These results support that the Th2 cytokine response plays a major role in the etiopathogenesis of pemphigus vulgaris.
引用
收藏
页码:25 / 30
页数:6
相关论文
共 43 条
  • [1] Alecu M, 1999, Roum Arch Microbiol Immunol, V58, P121
  • [2] A randomized double-blind trial of intravenous immunoglobulin for pemphigus
    Amagai, Masayuki
    Ikeda, Shigaku
    Shimizu, Hiroshi
    Iizuka, Hajime
    Hanada, Katsumi
    Aiba, Setsuya
    Kaneko, Fumio
    Izaki, Seiichi
    Tamaki, Kunihiko
    Ikezawa, Zenro
    Takigawa, Masahiro
    Seishima, Mariko
    Tanaka, Toshihiro
    Miyachi, Yoshiki
    Katayama, Ichiro
    Horiguchi, Yuji
    Miyagawa, Sachiko
    Furukawa, Fukumi
    Iwatsuki, Keiji
    Hide, Michihiro
    Tokura, Yoshiki
    Furue, Masutaka
    Hashimoto, Takashi
    Ihn, Hironobu
    Fujiwara, Sakuhei
    Nishikawa, Takeji
    Ogawa, Hideoki
    Kitajima, Yasuo
    Hashimoto, Koji
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 60 (04) : 595 - 603
  • [3] Autoreactive T cells in the immune pathogenesis of pemphigus vulgaris
    Amber, Kyle T.
    Staropoli, Patrick
    Shiman, Michael I.
    Elgart, George W.
    Hertl, Michael
    [J]. EXPERIMENTAL DERMATOLOGY, 2013, 22 (11) : 699 - 704
  • [4] Lesional Th17 cells and regulatory T cells in bullous pemphigoid
    Arakawa, Masataka
    Dainichi, Teruki
    Ishii, Norito
    Hamada, Takahiro
    Karashima, Tadashi
    Nakama, Takekuni
    Yasumoto, Shinichiro
    Tsuruta, Daisuke
    Hashimoto, Takashi
    [J]. EXPERIMENTAL DERMATOLOGY, 2011, 20 (12) : 1022 - 1024
  • [5] Lesional Th17 cells in pemphigus vulgaris and pemphigus foliaceus
    Arakawa, Masataka
    Dainichi, Teruki
    Yasumoto, Shinichiro
    Hashimoto, Takashi
    [J]. JOURNAL OF DERMATOLOGICAL SCIENCE, 2009, 53 (03) : 228 - 231
  • [6] Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris
    Behzad, M.
    Moebs, C.
    Kneisel, A.
    Moeller, M.
    Hoyer, J.
    Hertl, M.
    Eming, R.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2012, 166 (04) : 844 - 852
  • [7] Presence of interleukin 10 in the serum and blister fluid of patients with pemphigus vulgaris and pemphigoid
    Bhol, KC
    Rojas, AI
    Khan, IU
    Ahmed, AR
    [J]. CYTOKINE, 2000, 12 (07) : 1076 - 1083
  • [8] Interleukin-4 receptor in moderate atopic asthma - A phase I/II randomized, placebo-controlled trial
    Borish, LC
    Nelson, HS
    Lanz, MJ
    Claussen, L
    Whitmore, JB
    Agosti, JM
    Garrison, L
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 160 (06) : 1816 - 1823
  • [9] Chiricozzi A, 2012, J BIOL REG HOMEOS AG, V26, P165
  • [10] Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis - A randomized, double-blind, placebo-controlled, dose-escalation trial
    Choy, EHS
    Isenberg, DA
    Garrood, T
    Farrow, S
    Ioannou, Y
    Bird, H
    Cheung, N
    Williams, B
    Hazleman, B
    Price, R
    Yoshizaki, K
    Nishimoto, N
    Kishimoto, T
    Panayi, GS
    [J]. ARTHRITIS AND RHEUMATISM, 2002, 46 (12): : 3143 - 3150